Important Guidelines for Choosing a Medical Animator
This article is a reprint from Pharmaceutical Executive Magazine and has been shortened for purposes of this blog.
Want to learn more about effective visual communication tools? Our media partners, Viscira will be joining us in less than two weeks at the ePharma Summit. There's still time to register, as a reader of this blog you'll receive 10% off by mentioning code XP1806BLOG when you join. To view our full program, download our brochure. We hope to see you March 4-6 in NYC! (Source: ePharma Summit)
Source: ePharma Summit - February 22, 2013 Category: Medical Marketing and PR Tags: Digital Marketing for Pharma ePharma Source Type: blogs
Tamoxifen has my head spinning
Wednesday, February 20, 2013Current mood: ScaredSo yesterday was my 6 month Oncology Checkup. I loathe my 6 month checkups. Not at that fact that I have to see the Dr. but at the fact that I have to step back in time and relive my cancer all over again. Yesterday was particularly fun in the fact that I had to once again have a conversation about taking Tamoxifen....My cancer was ER/PR+ and Her2+. I took precautions against the Her2+ part of my cancer and took a drug called Herceptin every 3 weeks for a year via an IV. I did not experience any side affects with this dr...
Source: Sharing My Cancer Crapness - February 20, 2013 Category: Cancer Source Type: blogs
Tips for Maximizing iPad Effectiveness for Product Promotion and Education
Today's guest post comes from Noël Ashekian, Marketing Communications Manager at Viscira. She can be reached at nashekian@viscira.com
With physicians being among the biggest adopters of the Apple iPad, it is no surprise that it has become a key part of a pharma sales rep’s toolkit. A 2012 Manhattan Research report confirmed that 65 percent of “ePharma” docs who met face-to-face with pharma salespeople used an iPad, representing an increase from 30 percent in 2011.
Given the growing use of the iPad by pharma reps as a means to interact with HCPs, we thought it would be helpful to provide pharma brand marketing mana...
Source: ePharma Summit - February 20, 2013 Category: Medical Marketing and PR Tags: Companies attending ePharma 2013 epharma summit Digital Pharma Marketing Source Type: blogs
2012: Banner Year for New Drugs
Fueled by new cancer therapeutics, last year the annual new molecular and biological entity approval count from the U.S. Food and Drug Administration (FDA) saw its highest year since 1997. One-third of the novel products approved by the FDA’s Center for Drug Evaluation and Research (CDER) are used to treat cancers of the blood, breast, colon, prostate, skin and thyroid.
As part of the U.S. Food and Drug Administration (FDA), the Center for Drug Evaluation and Research (CDER) promotes and protects the health of Americans by assuring that all prescription and over-the-counter drugs are safe and effective. The CDE...
Source: Highlight HEALTH - February 13, 2013 Category: Medical Scientists Authors: Walter Jessen, Ph.D. Source Type: blogs
Herceptin Pricing In India Is A Joke: Menon Explains
Last week, the Indian government moved closer to issuing compulsory licenses on three widely used cancer medications – including Roche’s Herceptin – in hopes of making these treatments more affordable to a wider swath of its population (back story). The effort comes a year after India issued its first compulsory license for a brand-name drug, Bayer’s Nexavar cancer treatment, a move that has multinational drugmakers concerned. The cost per dose for Herceptin is roughly $1,400 per month, although Roche maintains it has taken steps to widen access, such as lowering the price previously and arranging f...
Source: Pharmalot - January 24, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Bayer Compulsory License Compusory Licensing Herceptin Nexavar Roche Source Type: blogs
India To Issue Compulsory Licenses On Cancer Meds
In the latest move destined to make global drugmakers bristle, the Indian government is taking steps to issue compulsory licenses on three widely used cancer medications in hopes of making these treatments more affordable to a wider swath of its population, according to The Indian Express.
The effort comes a year after India awarded a compulsory license to a generic drugmaker to produce a lower-cost version of a Bayer drug called Nexavar that is used to treat kidney and liver cancer, a step that was regarded as a landmark decision at the time and was predicted to usher in still more licenses. After the license was issued, ...
Source: Pharmalot - January 14, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Bayer Breast Cancer Bristol Myers Squibb Compulsory License Gleevec Glivec Herceptin Novartis Roche Source Type: blogs
Reactive Oxygen Species Are Your Friends!
The line under James Watson's name reads, of course, "Co-discoverer of DNA. Nobel Prize". But it could also read "Provocateur", since he's been pretty good at that over the years. He seems to have the right personality for it - both The Double Helix (fancy new edition there) and its notorious follow-up volume Avoid Boring People illustrate the point. There are any number of people who've interacted with him over the years who can't stand the guy.
But it would be a simpler world if everyone that we found hard to take was wrong about everything, wouldn't it? I bring this up because Watson has published an article, again del...
Source: In the Pipeline - January 11, 2013 Category: Chemists Tags: Cancer Source Type: blogs
Micropapillary Carcinoma of the Breast
-Micropapillary breast carcinoma (or invasive micropapillary carcinoma IMPC) is a type of otherwise 'typical' invasive ductal carcinoma which exhibits a unique and characteristic growth pattern. -Invasive micropapillary breast carcinoma is a very aggressive form of breast cancer, with a very high rate of lymph node metastasis.(The rate of lymph node involvement is estimated at between 75% and 100%).-Skin invovlement (skin retraction) is another occassional feature of invasive micropapillary carcinoma of the breast, and is observed in about 20-23% of all cases.Histological aspects of invasive micropapillary carcinoma o...
Source: Oncopathology - October 24, 2012 Category: Cancer & Oncology Tags: breast breast cancer carcinoma micropapillary poor prognosis Source Type: blogs
Minimal Reporting Guidelines for the Treatment of Cancer Patients
Minimal Reporting Guidelines for the Treatment of Cancer Patients As laboratory physicians, our contribution to patient care is knowledge: this is the starting point from which all informed therapeutic intervention proceeds. How that knowledge is obtained and communicated is the art and science of our profession. These minimal diagnostic guidelines are designed to be used as an aid, not a constraint, in that process. The guidelines are presented in a specific format out of necessity, but any format that effectively communicates the necessary information in a given patho...
Source: Oncopathology - September 5, 2011 Category: Cancer & Oncology Source Type: blogs
